Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0914 Fin QTs
BioCentury & Getty Images

Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more 

Sep 15, 2020 | 1:33 AM GMT

Escient raises $77.5M B round
Escient Pharmaceuticals Inc. announced Monday the start of a Phase I/Ib trial of lead program EP547 for cholestatic and

Read the full 491 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE